Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole

To test the hypothesis that Helicobacter pylori infection is associated with a decreased intragastric acidity during omeprazole therapy, ambulatory 24 hour dual point gastric pH recordings were performed in 18 H pylori positive and 14 H pylori negative subjects. There was a four to six week washout...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gut 1995-04, Vol.36 (4), p.539-543
Hauptverfasser: Verdú, E F, Armstrong, D, Fraser, R, Viani, F, Idström, J P, Cederberg, C, Blum, A L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 543
container_issue 4
container_start_page 539
container_title Gut
container_volume 36
creator Verdú, E F
Armstrong, D
Fraser, R
Viani, F
Idström, J P
Cederberg, C
Blum, A L
description To test the hypothesis that Helicobacter pylori infection is associated with a decreased intragastric acidity during omeprazole therapy, ambulatory 24 hour dual point gastric pH recordings were performed in 18 H pylori positive and 14 H pylori negative subjects. There was a four to six week washout period between the two pH recordings made in each subject after one week courses of placebo or omeprazole, 20 mg daily. During placebo, median 24 hour pH values were not different in the corpus (H pylori positive = 1.5, negative = 1.4; p = 0.9) or antrum (H pylori positive = 1.3, negative = 1.2; p = 0.1). However, during omeprazole treatment, median 24 hour pH values were higher in H pylori positive subjects, both in the corpus (H pylori positive = 5.5, negative = 4.0; p = 0.001) and antrum (H pylori positive = 5.5, negative = 3.5; p = 0.0004). During placebo treatment, the only difference between the two groups was a higher later nocturnal pH in the antrum in the H pylori positive group. During omeprazole treatment, gastric pH was higher both in the corpus and in the antrum in the H pylori positive group for all periods, except for mealtime in the corpus. These data indicate that omeprazole produces a greater decrease in gastric acidity in subjects with H pylori infection than in those who are H pylori negative. It is not, however, known whether there is a causal relationship between H pylori infection and increased omeprazole efficacy.
doi_str_mv 10.1136/gut.36.4.539
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1382493</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3969976411</sourcerecordid><originalsourceid>FETCH-LOGICAL-b535t-c4387d25129a5dce4fae85f6df71923433a659cc0bd810bde06fbb3e6a10dc023</originalsourceid><addsrcrecordid>eNp9kc2LFDEUxIMo67h68yoEFL3YY9L57Isgw-roLoqwLt5COp3MZuzutElaXf96M84wqAcv7x3qR71KCoCHGC0xJvzFZs5Lwpd0yUhzCyww5bIitZS3wQIhLComaHMX3EtpixCSssEn4EQIIhhHC_D5zDlrMgwOrm3vTWi1yTbC6aYP0cOUdZ4TDCP0Y456o1OO3sBpDbs5-nEDc7Q6D3bM8LvP1zAMdor6Z-jtfXDH6T7ZB4d9Cj69PrtcrauLD2_erl5dVC0jLFeGEim6muG60awzljptJXO8cwI3NaGEaM4aY1DbSVyGRdy1LbFcY9QZVJNT8HLvO83tYIvDLmevpugHHW9U0F79rYz-Wm3CN4WJrGlDisHTg0EMX2ebshp8Mrbv9WjDnJQQNavLvxXw8T_gNsxxLI9TWAiEGOe_qed7ysSQUrTuGAUjtetLlb5UWVSVvgr-6M_4R_hQUNGfHHSdjO5d1KPx6YgRyhskdlerPeZTtj-Oso5fFN85qfdXK3V1eS4_rsi5elf4Z3u-Hbb_D_gLhja7yw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1770056688</pqid></control><display><type>article</type><title>Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Verdú, E F ; Armstrong, D ; Fraser, R ; Viani, F ; Idström, J P ; Cederberg, C ; Blum, A L</creator><creatorcontrib>Verdú, E F ; Armstrong, D ; Fraser, R ; Viani, F ; Idström, J P ; Cederberg, C ; Blum, A L</creatorcontrib><description>To test the hypothesis that Helicobacter pylori infection is associated with a decreased intragastric acidity during omeprazole therapy, ambulatory 24 hour dual point gastric pH recordings were performed in 18 H pylori positive and 14 H pylori negative subjects. There was a four to six week washout period between the two pH recordings made in each subject after one week courses of placebo or omeprazole, 20 mg daily. During placebo, median 24 hour pH values were not different in the corpus (H pylori positive = 1.5, negative = 1.4; p = 0.9) or antrum (H pylori positive = 1.3, negative = 1.2; p = 0.1). However, during omeprazole treatment, median 24 hour pH values were higher in H pylori positive subjects, both in the corpus (H pylori positive = 5.5, negative = 4.0; p = 0.001) and antrum (H pylori positive = 5.5, negative = 3.5; p = 0.0004). During placebo treatment, the only difference between the two groups was a higher later nocturnal pH in the antrum in the H pylori positive group. During omeprazole treatment, gastric pH was higher both in the corpus and in the antrum in the H pylori positive group for all periods, except for mealtime in the corpus. These data indicate that omeprazole produces a greater decrease in gastric acidity in subjects with H pylori infection than in those who are H pylori negative. It is not, however, known whether there is a causal relationship between H pylori infection and increased omeprazole efficacy.</description><identifier>ISSN: 0017-5749</identifier><identifier>EISSN: 1468-3288</identifier><identifier>EISSN: 1458-3288</identifier><identifier>DOI: 10.1136/gut.36.4.539</identifier><identifier>PMID: 7737560</identifier><identifier>CODEN: GUTTAK</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and British Society of Gastroenterology</publisher><subject>Adult ; Biological and medical sciences ; Breath Tests ; Cross-Over Studies ; Digestive system ; Double-Blind Method ; Female ; Gastric Acidity Determination ; Helicobacter Infections - drug therapy ; Helicobacter pylori ; Humans ; Hydrogen-Ion Concentration - drug effects ; Male ; Medical sciences ; Middle Aged ; Omeprazole - therapeutic use ; Pharmacology. Drug treatments ; Single-Blind Method ; Time Factors</subject><ispartof>Gut, 1995-04, Vol.36 (4), p.539-543</ispartof><rights>1995 INIST-CNRS</rights><rights>Copyright BMJ Publishing Group LTD Apr 1995</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b535t-c4387d25129a5dce4fae85f6df71923433a659cc0bd810bde06fbb3e6a10dc023</citedby><cites>FETCH-LOGICAL-b535t-c4387d25129a5dce4fae85f6df71923433a659cc0bd810bde06fbb3e6a10dc023</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1382493/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1382493/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3469078$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7737560$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Verdú, E F</creatorcontrib><creatorcontrib>Armstrong, D</creatorcontrib><creatorcontrib>Fraser, R</creatorcontrib><creatorcontrib>Viani, F</creatorcontrib><creatorcontrib>Idström, J P</creatorcontrib><creatorcontrib>Cederberg, C</creatorcontrib><creatorcontrib>Blum, A L</creatorcontrib><title>Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole</title><title>Gut</title><addtitle>Gut</addtitle><description>To test the hypothesis that Helicobacter pylori infection is associated with a decreased intragastric acidity during omeprazole therapy, ambulatory 24 hour dual point gastric pH recordings were performed in 18 H pylori positive and 14 H pylori negative subjects. There was a four to six week washout period between the two pH recordings made in each subject after one week courses of placebo or omeprazole, 20 mg daily. During placebo, median 24 hour pH values were not different in the corpus (H pylori positive = 1.5, negative = 1.4; p = 0.9) or antrum (H pylori positive = 1.3, negative = 1.2; p = 0.1). However, during omeprazole treatment, median 24 hour pH values were higher in H pylori positive subjects, both in the corpus (H pylori positive = 5.5, negative = 4.0; p = 0.001) and antrum (H pylori positive = 5.5, negative = 3.5; p = 0.0004). During placebo treatment, the only difference between the two groups was a higher later nocturnal pH in the antrum in the H pylori positive group. During omeprazole treatment, gastric pH was higher both in the corpus and in the antrum in the H pylori positive group for all periods, except for mealtime in the corpus. These data indicate that omeprazole produces a greater decrease in gastric acidity in subjects with H pylori infection than in those who are H pylori negative. It is not, however, known whether there is a causal relationship between H pylori infection and increased omeprazole efficacy.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Breath Tests</subject><subject>Cross-Over Studies</subject><subject>Digestive system</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Gastric Acidity Determination</subject><subject>Helicobacter Infections - drug therapy</subject><subject>Helicobacter pylori</subject><subject>Humans</subject><subject>Hydrogen-Ion Concentration - drug effects</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Omeprazole - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Single-Blind Method</subject><subject>Time Factors</subject><issn>0017-5749</issn><issn>1468-3288</issn><issn>1458-3288</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kc2LFDEUxIMo67h68yoEFL3YY9L57Isgw-roLoqwLt5COp3MZuzutElaXf96M84wqAcv7x3qR71KCoCHGC0xJvzFZs5Lwpd0yUhzCyww5bIitZS3wQIhLComaHMX3EtpixCSssEn4EQIIhhHC_D5zDlrMgwOrm3vTWi1yTbC6aYP0cOUdZ4TDCP0Y456o1OO3sBpDbs5-nEDc7Q6D3bM8LvP1zAMdor6Z-jtfXDH6T7ZB4d9Cj69PrtcrauLD2_erl5dVC0jLFeGEim6muG60awzljptJXO8cwI3NaGEaM4aY1DbSVyGRdy1LbFcY9QZVJNT8HLvO83tYIvDLmevpugHHW9U0F79rYz-Wm3CN4WJrGlDisHTg0EMX2ebshp8Mrbv9WjDnJQQNavLvxXw8T_gNsxxLI9TWAiEGOe_qed7ysSQUrTuGAUjtetLlb5UWVSVvgr-6M_4R_hQUNGfHHSdjO5d1KPx6YgRyhskdlerPeZTtj-Oso5fFN85qfdXK3V1eS4_rsi5elf4Z3u-Hbb_D_gLhja7yw</recordid><startdate>19950401</startdate><enddate>19950401</enddate><creator>Verdú, E F</creator><creator>Armstrong, D</creator><creator>Fraser, R</creator><creator>Viani, F</creator><creator>Idström, J P</creator><creator>Cederberg, C</creator><creator>Blum, A L</creator><general>BMJ Publishing Group Ltd and British Society of Gastroenterology</general><general>BMJ</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19950401</creationdate><title>Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole</title><author>Verdú, E F ; Armstrong, D ; Fraser, R ; Viani, F ; Idström, J P ; Cederberg, C ; Blum, A L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b535t-c4387d25129a5dce4fae85f6df71923433a659cc0bd810bde06fbb3e6a10dc023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Breath Tests</topic><topic>Cross-Over Studies</topic><topic>Digestive system</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Gastric Acidity Determination</topic><topic>Helicobacter Infections - drug therapy</topic><topic>Helicobacter pylori</topic><topic>Humans</topic><topic>Hydrogen-Ion Concentration - drug effects</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Omeprazole - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Single-Blind Method</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Verdú, E F</creatorcontrib><creatorcontrib>Armstrong, D</creatorcontrib><creatorcontrib>Fraser, R</creatorcontrib><creatorcontrib>Viani, F</creatorcontrib><creatorcontrib>Idström, J P</creatorcontrib><creatorcontrib>Cederberg, C</creatorcontrib><creatorcontrib>Blum, A L</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Gut</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Verdú, E F</au><au>Armstrong, D</au><au>Fraser, R</au><au>Viani, F</au><au>Idström, J P</au><au>Cederberg, C</au><au>Blum, A L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole</atitle><jtitle>Gut</jtitle><addtitle>Gut</addtitle><date>1995-04-01</date><risdate>1995</risdate><volume>36</volume><issue>4</issue><spage>539</spage><epage>543</epage><pages>539-543</pages><issn>0017-5749</issn><eissn>1468-3288</eissn><eissn>1458-3288</eissn><coden>GUTTAK</coden><abstract>To test the hypothesis that Helicobacter pylori infection is associated with a decreased intragastric acidity during omeprazole therapy, ambulatory 24 hour dual point gastric pH recordings were performed in 18 H pylori positive and 14 H pylori negative subjects. There was a four to six week washout period between the two pH recordings made in each subject after one week courses of placebo or omeprazole, 20 mg daily. During placebo, median 24 hour pH values were not different in the corpus (H pylori positive = 1.5, negative = 1.4; p = 0.9) or antrum (H pylori positive = 1.3, negative = 1.2; p = 0.1). However, during omeprazole treatment, median 24 hour pH values were higher in H pylori positive subjects, both in the corpus (H pylori positive = 5.5, negative = 4.0; p = 0.001) and antrum (H pylori positive = 5.5, negative = 3.5; p = 0.0004). During placebo treatment, the only difference between the two groups was a higher later nocturnal pH in the antrum in the H pylori positive group. During omeprazole treatment, gastric pH was higher both in the corpus and in the antrum in the H pylori positive group for all periods, except for mealtime in the corpus. These data indicate that omeprazole produces a greater decrease in gastric acidity in subjects with H pylori infection than in those who are H pylori negative. It is not, however, known whether there is a causal relationship between H pylori infection and increased omeprazole efficacy.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and British Society of Gastroenterology</pub><pmid>7737560</pmid><doi>10.1136/gut.36.4.539</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0017-5749
ispartof Gut, 1995-04, Vol.36 (4), p.539-543
issn 0017-5749
1468-3288
1458-3288
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1382493
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection
subjects Adult
Biological and medical sciences
Breath Tests
Cross-Over Studies
Digestive system
Double-Blind Method
Female
Gastric Acidity Determination
Helicobacter Infections - drug therapy
Helicobacter pylori
Humans
Hydrogen-Ion Concentration - drug effects
Male
Medical sciences
Middle Aged
Omeprazole - therapeutic use
Pharmacology. Drug treatments
Single-Blind Method
Time Factors
title Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T08%3A50%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Helicobacter%20pylori%20status%20on%20intragastric%20pH%20during%20treatment%20with%20omeprazole&rft.jtitle=Gut&rft.au=Verd%C3%BA,%20E%20F&rft.date=1995-04-01&rft.volume=36&rft.issue=4&rft.spage=539&rft.epage=543&rft.pages=539-543&rft.issn=0017-5749&rft.eissn=1468-3288&rft.coden=GUTTAK&rft_id=info:doi/10.1136/gut.36.4.539&rft_dat=%3Cproquest_pubme%3E3969976411%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1770056688&rft_id=info:pmid/7737560&rfr_iscdi=true